Ascentage Pharma has developed a robust pipeline of 8 clinical-stage small molecule drug candidates, currently being evaluated in more than 40 Phase I or II clinical trials in the United StatesAustralia, and China.

 

Candidate Mechanism Lead Indications Preclinical Phase I Phase II NDA Countries
HQP1351* BCR-ABL Mutant Resistant CML
China
U.S.
KIT GIST
China
APG-2575 Bcl-2 Selective CLL/SLL
U.S. & Australia
WM
U.S. & Australia
AML
China
APG-1252 Bcl-2/Bcl-xL SCLC/NSCLC  
China, U.S. & Australia
NSCLC (Combo)
China
APG-115 MDM2-p53 Solid Tumors (IO Combo)  
U.S. & Australia
AML
China & U.S.
APG-1387 IAP Dimer Solid Tumors (IO Combo)
China & U.S.
Hepatitis B
China
AT-101 Bcl-2/Bcl-xL/Mcl-1 CLL
China & U.S. & Australia
APG-2449 FAK/ALK/ROS1 NSCLC
China
HQP8361 c-Met Selective Cancer (c-Met+)
China
Preclinical
AS00491 Mcl-1 Oncology
China & U.S.
APG-3526 Mcl-1 Oncology
China & U.S.
APG-5918 EED Selective Oncology
China & U.S.
AS1266 BCR-ABL CML
China & U.S.
UBX1967/1325 Bcl-2 Ophthalmology
U.S.
| *Pivotal Phase II Studies.       | *Submitted New Drug Application in China.